Zoetis - ZTS Stock Forecast, Price & News

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Analyst Ratings Changes

ZTS has been the topic of a number of recent research reports. Stifel Nicolaus decreased their price target on shares of Zoetis from $275.00 to $225.00 and set a "buy" rating on the stock in a research note on Friday, June 24th. Piper Sandler started coverage on shares of Zoetis in a research report on Monday, July 11th. They set an "overweight" rating and a $205.00 price objective on the stock. William Blair reiterated an "outperform" rating on shares of Zoetis in a research report on Friday, August 5th. The Goldman Sachs Group cut their price target on shares of Zoetis from $208.00 to $202.00 and set a "buy" rating on the stock in a report on Thursday, July 21st. Finally, StockNews.com cut shares of Zoetis from a "strong-buy" rating to a "buy" rating in a report on Tuesday, April 26th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $224.14.

Zoetis Stock Performance

ZTS Stock opened at $170.17 on Friday. The firm has a market cap of $79.66 billion, a price-to-earnings ratio of 38.59, a PEG ratio of 3.00 and a beta of 0.73. The firm has a 50-day simple moving average of $172.22 and a two-hundred day simple moving average of $179.85. Zoetis has a one year low of $154.18 and a one year high of $249.27. The company has a debt-to-equity ratio of 1.14, a quick ratio of 1.46 and a current ratio of 2.18.

Zoetis (NYSE:ZTS - Get Rating) last released its quarterly earnings results on Thursday, August 4th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.22 by ($0.02). The firm had revenue of $2.10 billion for the quarter, compared to analysts' expectations of $2.03 billion. Zoetis had a net margin of 26.14% and a return on equity of 49.03%. The business's quarterly revenue was up 7.8% compared to the same quarter last year. During the same period in the previous year, the company posted $1.19 earnings per share. On average, equities analysts forecast that Zoetis will post 5.01 EPS for the current fiscal year.

Insider Activity at Zoetis

In related news, CEO Kristin C. Peck sold 311 shares of the stock in a transaction that occurred on Thursday, July 7th. The shares were sold at an average price of $180.00, for a total value of $55,980.00. Following the completion of the transaction, the chief executive officer now directly owns 39,743 shares of the company's stock, valued at approximately $7,153,740. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Kristin C. Peck sold 311 shares of the stock in a transaction that occurred on Thursday, July 7th. The shares were sold at an average price of $180.00, for a total value of $55,980.00. Following the completion of the transaction, the chief executive officer now directly owns 39,743 shares of the company's stock, valued at approximately $7,153,740. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Willie M. Reed sold 1,855 shares of the firm's stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $162.31, for a total transaction of $301,085.05. Following the transaction, the director now directly owns 6,782 shares of the company's stock, valued at $1,100,786.42. The disclosure for this sale can be found here. Insiders sold 18,356 shares of company stock valued at $3,250,158 in the last three months. 0.12% of the stock is owned by insiders.